2019 EULAR/ACR 狼疮分类标准在拉丁美洲队列中的早期分类表现
该研究在拉丁美洲多ethnic多中心队列中,以1982/1997 ACR标准为金标准,评估2019 EULAR/ACR SLE分类标准的敏感性为91.3%,且较1982/1997 ACR和2012 SLICC标准分别提前7.4%(平均0.67年)和0.6%(平均1.47年)分类少数患者。结论认为2019 EULAR/ACR标准仅使小部分患者更早分类,全球采纳前需更多研究。
要点
- 2019 EULAR/ACR标准敏感性91.3%(以1982/1997 ACR为金标准)。
- 较1982/1997 ACR提前分类7.4%(平均0.67年),较2012 SLICC提前0.6%(平均1.47年)。
- 提前分类者更常见高滴度抗dsDNA;延迟分类者黏膜皮肤和关节表现较少。
核心结论
- 2019 EULAR/ACR标准在拉丁美洲真实临床实践中仅使小部分患者较1982/1997 ACR或2012 SLICC标准更早分类。
研究设计与样本
- 拉丁美洲多ethnic多中心队列研究,SLE定义采用医师诊断,以1982/1997 ACR标准为金标准计算2019 EULAR/ACR标准的敏感性。
主要发现
- 2019 EULAR/ACR标准敏感性为91.3%(以1982/1997 ACR为金标准)。
- 2019 EULAR/ACR标准较1982/1997 ACR标准提前分类7.4%患者(平均0.67年),较2012 SLICC标准提前分类0.6%患者(平均1.47年)。
- 较1982/1997 ACR提前分类者更可能有高抗dsDNA滴度;延迟分类者黏膜皮肤和关节表现较少。
关键数值与推荐
- 2019 EULAR/ACR标准敏感性91.3%(以1982/1997 ACR为金标准)。
- 提前分类比例:较1982/1997 ACR为7.4%(平均0.67年),较2012 SLICC为0.6%(平均1.47年)。
临床怎么用
- 在拉丁美洲患者中,2019 EULAR/ACR标准可识别多数SLE患者,但仅少数较旧标准更早分类。
局限性
- 结论基于拉丁美洲多ethnic队列,全球采纳前需在不同人群进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the performance of the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) criteria in terms of earlier patients' classification in comparison to the 1982/1997 ACR or the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria. MATERIALS AND METHODS: Patients from a Latin America, multiethnic, multicentre cohort, where SLE was defined using the physicians' diagnosis, were included. To calculate the sensitivity of the 2019 EULAR/ACR criteria, the 1982/1997 ACR criteria were considered the gold standard. Additionally, comparison of the 1982/1997 ACR criteria and the 2012 SLICC criteria with the 2019 EULAR/ACR criteria was performed. RESULTS: The sensitivity of the 2019 EULAR/ACR criteria when compared with the 1982/1997 ACR criteria as the gold standard was 91.3%. This new set of criteria allowed an earlier SLE patient classification in 7.4% (mean 0.67 years) and 0.6% (mean 1.47 years) than the 1982/1997 ACR and the 2012 SLICC criteria, respectively. Patients accruing the 2019 EULAR/ACR earlier than the 1982/1997 ACR criteria were more likely to have high anti-dsDNA titres; those accruing them later were less likely to have mucocutaneous and joint manifestations; this was not observed when comparing them with the 2012 SLICC criteria. CONCLUSIONS: The 2019 EULAR/ACR criteria classified earlier only a small proportion of Latin America patients than with the two other criteria sets in real-life clinical practice scenarios. Further studies in different patient populations are needed before these new criteria are adopted worldwide.
引用
- Pons-Estel GJ, Ugarte-Gil MF, Harvey GB, et al. Applying the 2019 EULAR/ACR lupus criteria to patients from an established cohort: a Latin American perspective. RMD Open. 2020. PMID: 31958284. doi:10.1136/rmdopen-2019-001097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。